Abstract | OBJECTIVE: METHODS: The study population comprised 45 consecutive patients with advanced hepatocellular carcinoma associated with tumor thrombosis in the main and/or first portal vein. A dose of 50-60 mg/m(2) epirubicin was administered from the proper, right, or left hepatic artery. Treatment was repeated every 4-12 weeks if there was no evidence of tumor progression or unacceptable toxicity. RESULTS: Of the 45 treated patients, 4 (9%) achieved a partial response, 12 (27%) had no change, and 29 (64%) showed progressive disease. The median survival time, 1-year survival rate and median time to progression were 6.0 months, 20.0%, and 1.1 months for all patients, respectively. The main grade 3 and 4 toxicities were leukopenia (27%), neutropenia (47%), thrombocytopenia (9%), and elevation of aspartate (36%) and alanine aminotransferases (13%). Febrile neutropenia was observed in 2 patients (4%). CONCLUSION:
|
Authors | Masafumi Ikeda, Takuji Okusaka, Hideki Ueno, Chigusa Morizane, Satoru Iwasa, Atsushi Hagihara, Yasushi Kojima |
Journal | Oncology
(Oncology)
Vol. 72
Issue 3-4
Pg. 188-93
( 2007)
ISSN: 1423-0232 [Electronic] Switzerland |
PMID | 18097170
(Publication Type: Journal Article)
|
Copyright | (c) 2007 S. Karger AG, Basel |
Chemical References |
- Antibiotics, Antineoplastic
- Epirubicin
|
Topics |
- Aged
- Antibiotics, Antineoplastic
(administration & dosage, adverse effects)
- Carcinoma, Hepatocellular
(complications, drug therapy, mortality)
- Epirubicin
(administration & dosage, adverse effects)
- Female
- Hepatic Artery
- Humans
- Infusions, Intra-Arterial
- Liver Neoplasms
(complications, drug therapy, mortality)
- Male
- Middle Aged
- Neoplasm Invasiveness
- Portal Vein
- Retrospective Studies
- Survival Analysis
- Venous Thrombosis
(drug therapy, etiology)
|